BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer

    June 2024 in “ ESMO Gastrointestinal Oncology ”
    Y. Matsubara, H. Bando, D. Kotani, Yoshinori Kagawa, K Harada, Hiroki Osumi, Naoki Izawa, Takahiro Kawakami, S. Boku, Tomoharu Matsumoto, M. Wakabayashi, T. Yoshino
    Image of study
    TLDR The combination treatment showed a higher response rate but no significant survival benefits.
    The BAYONET trial is a phase II study involving 30 patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who are refractory to encorafenib plus cetuximab (ENCO plus CET). It evaluates the efficacy and safety of a combination treatment with encorafenib, binimetinib, and cetuximab (ENCO, BINI, plus CET). The primary endpoint is the 12-week progression-free survival (PFS) rate. Although the triplet combination showed a higher response rate compared to the doublet, no significant survival benefits were observed. The study also investigates resistance mechanisms through circulating tumor DNA analysis and adheres to ethical guidelines.
    Discuss this study in the Community →